Moolec Science SA reported a significant profit of $92.0 million for the six-month period ended December 31, 2025, primarily driven by a $129.3 million gain from the deconsolidation of its subsidiaries, Bioceres S.A. and Bioceres LLC, following their bankruptcy proceedings. These events, alongside a business combination with Bioceres Group, Nutrecon, and Gentle Tech, have fundamentally altered the company's operational scope and financial position. Despite the reported profit, the company faces a negative working capital position and significant liquidity challenges, raising material uncertainty about its ability to continue as a going concern, though a $6 million credit line has been secured from a major shareholder.